Bortezomib (Velcade), Inhibitor

Bortezomib (Velcade)

Cat. Num. AAA385123

• Purity: >98%
• Synonyms: Bortezomib (Velcade); MG-341; PS-341; inhibitor

• Purity/Purification: >98%
• Form/Format: Powder
• Concentration: 0.1 mM: 26.03 mL (1 mg); 130.14 mL (5 mg); 260.28mL (10 mg); 0.5 mM: 5.21 mL (1 mg); 26.03 mL (5 mg); 52.06 mL (10 mg); 1 mM: 2.6 mL (1 mg); 13.01 mL (5 mg); 26.03 mL (10 mg); 5 mM: 0.52 mL (1 mg); 2.6 mL (5 mg); 5.21 mL (10 mg) (varies by lot)

• CAS Number: 179324-69-7
• Formula: C19H25BN4O4
• SMILES: B([C@H](CC(C)C)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)C2=NC=CN=C2)(O)O
• Actions: Inhibitor
• In Vivo Solvent: 0.5% methylcellulose/0.2% Tween 80
• Solubility (DMSO): 77 mg/mL (200.39 mM)
• Solubility (Ethanol): <1 mg/mL (<1 mM)
• Solubility (in vivo): 5 mg/mL
• Solubility (Water): <1 mg/mL (<1 mM)
• Availability: We cannot ship this item to Switzerland, Italy, Germany, France and Austria.
• Preparation and Storage: at -20 degree C 3 years Powder

Chemical Structure

Related Product Information for Bortezomib (Velcade), inhibitor

Bortezomib is a highly selective, reversible inhibitor of the 26S proteasome

References

A Hayano, .et al. Cell-type-specific sensitivity of bortezomib in the methotrexate-resistant primary central nervous system lymphoma cells, Int J Clin Oncol, 2019, 1-10
Hiroshi Fukamachi, .et al. A subset of diffuse-type gastric cancer is susceptible to mTOR inhibitors and checkpoint inhibitors, J Exp Clin Cancer Res, 2019, 38:127
Y Sato, .et al. S-like phase CDKs stabilize the Epstein-Barr virus BDLF4 protein to temporally control late gene transcription, J Virol, 2019, Jan 30. pii: JVI.01707-18 PMID: 30700607
Takashi Azuma, .et al. Removal of pharmaceuticals in water by introduction of ozonated microbubbles, SEP PURIF TECHNOL, 2019, Apr; 212: 483-489
Wenhan Deng, .et al. Variable Responses of MYC Translocation Positive Lymphoma Cell Lines To Different Combinations of Novel Agents: Impact of BCL2 Family Protein Expression, Transl Oncol, 2018, Oct; 11(5): 1147-1154 PMID: 30055346
Hirosumi Tamura, .et al. Evaluation of anticancer agents using patient-derived tumor organoids characteristically similar to source tissues, Oncol Rep, 2018, Aug; 40(2): 635-646 PMID: 29917168
Fujita KI, .et al. Involvement of the Transporters P-Glycoprotein and Breast Cancer Resistance Protein in Dermal Distribution of the Multikinase Inhibitor Regorafenib and Its Active Metabolites, J Pharm Sci, 2017, Sep;106(9):2632-2641 PMID: 28479358
Hokyung K. Chung, .et al. Tunable and reversible drug control of protein production via a self-excising degron, Nat Chem Biol, 2015, Sep; 11(9): 713-720. PMID: 26214256
S Raz, .et al. Severe hypoxia induces complete antifolate resistance in carcinoma cells due to cell cycle arrest, Cell Death Dis., 2014, 5(2): e1067 PMID: 24556682